|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 79.11 USD | -1.33% |
|
-6.79% | +24.50% |
| 07-14 | Cytokinetics Insider Sold Shares Worth $615,150, According to a Recent SEC Filing | MT |
| 07-07 | RBC Capital Adjusts Cytokinetics Price Target to $117 From $119, Maintains Outperform Rating | MT |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Assets | ||||||||||
Cash And Equivalents | 113M | 65.58M | 113M | 94.86M | 123M | |||||
Short Term Investments | 359M | 717M | 502M | 981M | 760M | |||||
Total Cash And Short Term Investments | 472M | 783M | 615M | 1.08B | 882M | |||||
Accounts Receivable, Total | 56.82M | 147K | 1.28M | 16.65M | 17.76M | |||||
Other Receivables | - | - | - | - | - | |||||
Total Receivables | 56.82M | 147K | 1.28M | 16.65M | 17.76M | |||||
Prepaid Expenses | 7.22M | 12.46M | 11.94M | 15.28M | 16.99M | |||||
Total Current Assets | 536M | 795M | 628M | 1.11B | 917M | |||||
Gross Property Plant And Equipment | 163M | 180M | 176M | 178M | 202M | |||||
Accumulated Depreciation | -16.19M | -17.09M | -28.35M | -37.18M | -47.3M | |||||
Net Property Plant And Equipment | 146M | 163M | 148M | 141M | 155M | |||||
Long-term Investments | 152M | 46.71M | 40.53M | 145M | 335M | |||||
Other Long-Term Assets, Total | 7.19M | 9.69M | 8M | 7.7M | 17.34M | |||||
Total Assets | 841M | 1.01B | 824M | 1.4B | 1.42B | |||||
Liabilities | ||||||||||
Accounts Payable, Total | 21.09M | 25.61M | 21.51M | 20.37M | 22.34M | |||||
Accrued Expenses, Total | 34.37M | 44.1M | 42.64M | 55.32M | 83.28M | |||||
Short-term Borrowings | - | - | - | 11.3M | 31.1M | |||||
Current Portion of Long-Term Debt | - | - | 10.08M | 11.52M | 41.18M | |||||
Current Portion of Leases | 14.86M | 13.83M | 18.88M | 19.18M | 19.11M | |||||
Unearned Revenue Current, Total | - | - | - | 52.37M | 1.61M | |||||
Other Current Liabilities | 1.54M | 1.08M | 9.57M | 9.61M | 3.83M | |||||
Total Current Liabilities | 71.86M | 84.62M | 103M | 180M | 202M | |||||
Long-Term Debt | 143M | 610M | 607M | 769M | 1.24B | |||||
Long-Term Leases | 112M | 128M | 121M | 113M | 108M | |||||
Unearned Revenue Non Current | 266M | 301M | 380M | 462M | 521M | |||||
Other Non Current Liabilities | 4.46M | 43K | 33K | 14M | 13.7M | |||||
Total Liabilities | 597M | 1.12B | 1.21B | 1.54B | 2.08B | |||||
Common Stock, Total | 84K | 94K | 102K | 118K | 123K | |||||
Additional Paid In Capital | 1.45B | 1.48B | 1.73B | 2.56B | 2.83B | |||||
Retained Earnings | -1.21B | -1.59B | -2.11B | -2.7B | -3.49B | |||||
Comprehensive Income and Other | -869K | -3.59M | -10K | 2.4M | 630K | |||||
Total Common Equity | 244M | -108M | -386M | -135M | -660M | |||||
Total Equity | 244M | -108M | -386M | -135M | -660M | |||||
Total Liabilities And Equity | 841M | 1.01B | 824M | 1.4B | 1.42B | |||||
Supplemental Items | ||||||||||
ECS Total Shares Outstanding on Filing Date | 84.86M | 95.16M | 103M | 118M | 123M | |||||
ECS Total Common Shares Outstanding | 84.8M | 94.83M | 102M | 118M | 123M | |||||
Book Value / Share | 2.88 | -1.14 | -3.8 | -1.15 | -5.37 | |||||
Tangible Book Value | 244M | -108M | -386M | -135M | -660M | |||||
Tangible Book Value Per Share | 2.88 | -1.14 | -3.8 | -1.15 | -5.37 | |||||
Total Debt | 270M | 751M | 757M | 923M | 1.44B | |||||
Net Debt | -202M | -31.23M | 142M | -153M | 557M | |||||
Debt Equivalent Oper. Leases | - | - | - | - | - | |||||
Account Code - Inventory Valuation | 3 | - | 3 | 3 | 3 | |||||
Machinery, Total | 27.48M | 28.45M | 28.16M | 30.82M | 35.32M | |||||
Full Time Employees | 253 | 409 | 423 | 498 | 673 |
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















